Search
David Grimwade Award
In 2017, EHA established a new award in honor of the late David Grimwade, for his great involvement and contribution to the European Hematology Association and its scientific activities as Board Member, TRTH Co-Director and Chair of the Scientific Program…
Read moreEHA Exam
An annual assessment designed to test your knowledge of the European Hematology Curriculum. EHA Exam 2025
The 9th European Hematology Exam will take place on June 12, 2025, from 13:30–16:00 (CEST).
Highlights of Past EHA (HOPE) Middle East and North Africa (MENA) 2021 - report
The sixth HOPE MENA, with highlights of the EHA Annual Congress, successfully concluded September 23-24. Fully virtual for the second year in a row, the program was compiled together with eight regional partner societies.
Read moreEHA & ERN-EuroBloodNet Spotlight on Hypereosinophilic Syndrome Webinars
An accredited European online educational program for health professionals, organized by EHA and ERN-EuroBloodNet. DatesThe sessions will take place on :
Monday, April 15, 2024 at 17:00 (CEST). Monday, May 13, 2024 at 17:00 (CEST).
Brussels Declaration on the Recognition of Professional QualificationsThe future of the Harmonisation of the Haematology Curriculum in Europe
On the occasion of the meeting, there was unanimous support for the
“Brussels Declaration on the Recognition of Professional Qualifications” that follows:
The mobility of haematology trainees is of the utmost importance.
EHA reaffirms commitment to hematology's future with new brand identity
The European Hematology Association (EHA) is thrilled to announce the launch of our new brand identity. This includes a refreshed logo, updated color palette, and a new slogan, marking a significant milestone in our journey.
Read moreRestoring Effective Anti-Tumor Response in Hodgkin Lymphoma with Nivolumab
Hodgkin Lymphoma typically affects young men and women in their 30s. Although it is highly curable with the current combination of chemo and radiation therapy, approximately 20% of patients will not be cured with first line regimens.
Read moreBreakthrough results in European multicenter trial on acute promyelocytic leukemia (APL): no more chemotherapy?
APL is a rare, yet aggressive, subtype of acute myeloid leukemia (AML) characterized by a maturation arrest of white blood cell precursors in the marrow, leading to a shortage of normal white cells and platelets in the blood, which is…
Read more- «
- 1
- 2
- 3
- 4
- 5
- 6
- 7
- 8
- 9
- 10
- 11
- 12
- 13
- 14
- 15
- 16
- 17
- 18
- 19
- 20
- 21
- 22
- 23
- 24
- 25
- 26
- 27
- 28
- 29
- 30
- 31
- 32
- 33
- 34
- 35
- 36
- 37
- 38
- 39
- 40
- 41
- 42
- 43
- 44
- 45
- 46
- 47
- 48
- 49
- 50
- 51
- 52
- 53
- 54
- 55
- 56
- 57
- 58
- 59
- 60
- 61
- 62
- 63
- 64
- 65
- 66
- 67
- 68
- 69
- 70
- 71
- 72
- 73
- 74
- 75
- 76
- 77
- 78
- 79
- 80
- 81
- 82
- 83
- 84
- 85
- 86
- 87
- 88
- 89
- 90
- 91
- 92
- 93
- 94
- 95
- 96
- 97
- 98
- 99
- 100
- 101
- 102
- 103
- 104
- 105
- 106
- 107
- 108
- 109
- 110
- 111
- 112
- 113
- 114
- 115
- 116
- 117
- 118
- 119
- 120
- 121
- 122
- 123
- 124
- 125
- 126
- 127
- 128
- 129
- 130
- 131
- 132
- 133
- 134
- 135
- 136
- 137
- 138
- 139
- 140
- 141
- 142
- 143
- 144
- 145
- 146
- »